Artiva Biotherapeutics, Inc. (ARTV) Earnings History
Annual and quarterly earnings data from 2020 to 2024
Loading earnings history...
ARTV EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
ARTV Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 100.0% | -26805.6% | -23304.0% |
| 2023 | 100.0% | -91.6% | -82.7% |
| 2022 | 100.0% | -1213.3% | -1184.1% |
| 2021 | 100.0% | -2660.9% | -3587.7% |
| 2020 | - | - | - |
Download Data
Export ARTV earnings history in CSV or JSON format
Free sign-in required to download data
Artiva Biotherapeutics, Inc. (ARTV) Earnings Overview
As of May 8, 2026, Artiva Biotherapeutics, Inc. (ARTV) reported trailing twelve-month net income of -$72M, reflecting -337.0% year-over-year growth. The company earned $-2.95 per diluted share over the past four quarters, with a net profit margin of -23304.0%.
Looking at the long-term picture, ARTV's historical earnings data spans multiple years. The company achieved its highest annual net income of -$18M in fiscal 2020.
Artiva Biotherapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including FATE (-$136M net income, -2051.1% margin), NKTR (-$164M net income, -297.1% margin), STTK (-$50M net income, -4880.9% margin), ARTV has room to improve margins relative to the peer group. Compare ARTV vs FATE →
ARTV Earnings vs Peers
Earnings metrics vs comparable public companies
ARTV Historical Earnings Data (2020–2024)
5 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$58M | -111.2% | -$67M | $-5.20 | -23304.0% | -26805.6% |
| 2023 | -$28M | +52.6% | -$31M | $-1.19 | -82.7% | -91.6% |
| 2022 | -$58M | +18.7% | -$60M | $-3.32 | -1184.1% | -1213.3% |
| 2021 | -$72M | -299.2% | -$53M | $-4.08 | -3587.7% | -2660.9% |
| 2020 | -$18M | - | -$18M | $-1.02 | - | - |
See ARTV's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ARTV Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ARTV vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonARTV — Frequently Asked Questions
Quick answers to the most common questions about buying ARTV stock.
Is ARTV growing earnings?
ARTV EPS fell to $-2.95, with earnings declining -337.0%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-72M.
What are ARTV's profit margins?
Artiva Biotherapeutics, Inc. net margin is -23304.0%, with operating margin at -26805.6%. Below-average margins reflect competitive or cost pressures.
How consistent are ARTV's earnings?
ARTV earnings data spans 2020-2024. The declining earnings trend is -337.0% YoY. Historical data enables comparison across business cycles.